A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
March 15, 2015
End Date
November 30, 2019
Administered By
School of Medicine
Awarded By
Ultragenyx Pharmaceutical
Start Date
March 15, 2015
End Date
November 30, 2019